Patients experiencing with both HIV and cancer face a complex therapeutic challenge. The interplay between these two diseases can lead to unique medical manifestations and present significant obstacles in achieving optimal results. Pharmacological combinations offer a promising approach for improving the care of this vulnerable patient segment. By